Hemangiopericytoma (HPC) / Solitary Fibrous Tumor (SFT) — a rare mesenchymal neoplasm unified under the single entity "solitary fibrous tumor" in the 2013 and 2020 World Health Organization Classification of Soft Tissue and Bone Tumors following the recognition that the spindle cell tumor originally described by Stout and Murray in 1942 as hemangiopericytoma and the pleural-based fibrous mesothelioma variant described by Klemperer and Rabin as "localized fibrous mesothelioma" share a defining molecular alteration — the NAB2-STAT6 gene fusion resulting from intrachromosomal inversion on chromosome 12q13 — that activates EGR1-responsive genes driving neoplastic proliferation through a pericyte-related cell of origin, unifying what had previously been classified as separate entities and explaining the characteristic STAT6 nuclear expression now used as a diagnostic immunohistochemical marker in all SFT regardless of anatomical location — can arise from any site in the body where pericytes exist, with the most common primary sites including the pleura (where SFT was historically classified as localized fibrous mesothelioma), meninges (accounting for approximately 2–4% of intracranial meningeal tumors under the historical designation meningeal hemangiopericytoma, now classified as CNS WHO grade 2 or grade 3 SFT/HPC by the WHO CNS Classification), retroperitoneum, extremity soft tissue, head and neck, and pelvic cavity, with rare cases arising in the orbit, nasal cavity, liver, and other visceral organs; SFT incidence is estimated at fewer than 1 case per million population annually, making it among the rarest soft tissue neoplasms in any single institution's experience, with a broad age range of presentation (peak incidence in the fifth and sixth decades) and no significant sex predilection except for pleural SFT which shows a slight male predominance. The NAB2-STAT6 fusion is detectable in virtually all SFT regardless of anatomical site or histologic grade by RNA sequencing, FISH, or reverse transcription-PCR, while STAT6 nuclear immunoreactivity (diffuse strong nuclear STAT6 by IHC) represents the surrogate diagnostic marker applicable in routine surgical pathology laboratories without molecular testing; the specific NAB2-STAT6 fusion variant (exon 4 of NAB2 fused to exon 2 of STAT6 versus exon 6 fused to exon 16-17) may correlate with histologic grade and clinical behavior in SFT of different anatomical compartments. Risk stratification models for SFT (including the Demicco risk stratification model incorporating patient age, tumor size, mitotic activity, and necrosis) identify SFT as spanning a biologic spectrum from tumors with very low recurrence risk (small, mitotically inactive, nonnecrotic SFT in favorable anatomical locations accessible for complete resection) to high-grade tumors with aggressive behavior, frequent metastasis to lung and liver, and poor prognosis, with intracranial SFT/HPC (CNS WHO grade 3) carrying approximately 30–50% distant metastasis rates at 10 years and local recurrence rates approaching 50–90% making it among the most challenging intracranial tumors in neurosurgery. Surgery achieving complete resection with negative margins (R0 resection) is the primary treatment for SFT across all anatomical sites; adjuvant radiation therapy is recommended for incompletely resected SFT and for intracranial SFT/HPC based on retrospective data; systemic therapy options for recurrent or metastatic SFT include anti-angiogenic agents (sunitinib, pazopanib, bevacizumab + temozolomide regimen with reported response rates of 20–30% in SFT), with the favorable tumor vascularity reflected in SFT's pericyte origin and characteristic "staghorn" vascular pattern potentially explaining sensitivity to VEGF pathway inhibitors; and the long natural history of SFT — where late recurrences and distant metastases may appear 10–20 years after initial complete resection — demands surveillance programs spanning decades of follow-up. Multidisciplinary SFT management integrates sarcoma surgery (wide local excision for extremity/trunk SFT, craniofacial and skull base surgery for head and neck SFT, neurosurgery for intracranial SFT/HPC), thoracic surgery (pleural SFT resection), radiation oncology (adjuvant IMRT for high-risk SFT and intracranial SFT/HPC), pathology (NAB2-STAT6 fusion confirmation, STAT6 IHC, Demicco risk stratification), medical oncology (anti-angiogenic therapy for recurrent/metastatic SFT), interventional radiology (preoperative embolization for highly vascular SFT), and long-term sarcoma surveillance programs — coordinated within sarcoma centers and neuro-oncology programs where SFT's rarity and anatomical diversity require concentrated multidisciplinary expertise.
SFT/HPC technology platforms — whether supporting sarcoma surgery programs coordinating wide local excision and reconstruction for extremity or retroperitoneal SFT (managing preoperative MRI for tumor characterization, vascular involvement mapping, surgical margin planning, preoperative embolization coordination with interventional radiology for hypervascular SFT, operative documentation, and postoperative pathology integration for Demicco risk stratification), neurosurgery programs managing intracranial SFT/HPC resection (preoperative MRI brain with gadolinium and angiography for vascular supply characterization, intraoperative neuronavigation, functional mapping for eloquent cortex-adjacent SFT/HPC, operative documentation for craniotomy and duraplasty, postoperative neurological assessment), radiation oncology platforms managing adjuvant IMRT for high-risk or incompletely resected SFT and intracranial SFT/HPC (treatment planning, dose-volume optimization, daily image guidance, stereotactic radiosurgery for recurrent intracranial SFT), pathology laboratories performing NAB2-STAT6 fusion testing and STAT6 IHC (molecular pathology for fusion variant identification, Demicco risk stratification with mitotic count, necrosis assessment, and tumor size documentation), medical oncology platforms managing anti-angiogenic therapy (sunitinib, pazopanib, bevacizumab-temozolomide regimens, toxicity monitoring, dose modification, tumor response assessment imaging scheduling), and long-term sarcoma surveillance platforms managing serial imaging for late recurrence detection across the 10–20-year follow-up period that SFT's late-recurrence biology demands — must maintain the availability and performance standards that SFT/HPC's surgical complexity, radiation precision, molecular diagnostics, and decade-spanning surveillance demands require. This guide explains why SFT/HPC tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the surgical, radiation, pathologic, and long-duration surveillance complexity of modern SFT/HPC management.
Why SFT/HPC Tech Platforms Require Specialized Monitoring Attention
SFT/HPC management is defined by the surgical complexity of wide local excision for retroperitoneal and intracranial SFT where proximity to major neurovascular structures makes achieving R0 margins challenging, the radiation planning complexity of adjuvant IMRT for intracranial SFT/HPC where brainstem and eloquent cortex dose constraints limit achievable tumor doses, the molecular diagnostic complexity of NAB2-STAT6 fusion confirmation and Demicco risk stratification that determine adjuvant treatment recommendations and surveillance intensity, the anti-angiogenic therapy management for recurrent and metastatic SFT where multitargeted kinase inhibitor toxicity requires careful monitoring, and the exceptionally long natural history of SFT requiring surveillance programs spanning 10–20 years. Technology failures in these domains create disruptions calibrated to the surgical, radiosurgical, pathologic, pharmacologic, and surveillance consequences of SFT/HPC's unique clinical profile.
Surgical planning platforms have critical impact during SFT resection. Wide local excision of retroperitoneal SFT — where MRI defines tumor relationship to major vessels (inferior vena cava, aorta, iliac vessels), adjacent organs (kidney, ureter, bowel), and perineural invasion, where preoperative embolization of feeding vessels reduces intraoperative hemorrhage from the characteristically hypervascular staghorn vascular pattern, and where intraoperative frozen sections assess resection margins — depends on platforms managing preoperative imaging, vascular map, embolization coordination, and operative documentation. Monitor surgical planning platforms at 1-minute intervals during operative sessions.
Neurosurgery platforms support intracranial SFT/HPC resection. Craniotomy for intracranial SFT/HPC — where intraoperative neuronavigation guides resection of meningeal-based tumors with potential involvement of venous sinuses (superior sagittal sinus, transverse sinus), where functional mapping identifies eloquent cortex requiring preservation, where preoperative embolization reduces the highly vascular SFT's intraoperative blood loss, and where the extent of resection determines adjuvant radiation recommendation and local recurrence risk — requires continuous platform availability during operative sessions. Monitor neurosurgery platforms at 1-minute intervals during operative hours.
Radiation therapy platforms determine adjuvant IMRT delivery for SFT/HPC. Adjuvant IMRT for incompletely resected SFT and intracranial SFT/HPC (WHO grade 2–3) — where treatment planning optimizes dose to the tumor bed and margin while respecting optic apparatus, brainstem, and spinal cord constraints, where stereotactic radiosurgery may be used for recurrent intracranial SFT, and where fractionated stereotactic radiation requires daily image guidance — requires continuous platform availability during treatment sessions. Monitor radiation therapy platforms at 1-minute intervals during treatment hours.
Molecular pathology platforms confirm NAB2-STAT6 fusion and risk stratification. Definitive SFT diagnosis requires STAT6 nuclear IHC and/or NAB2-STAT6 fusion confirmation by molecular testing — the diagnostic distinction from synovial sarcoma (SS18-SSX fusion, TLE1 IHC), solitary fibrous tumor mimics (STAT6 nuclear negative), and desmoid fibromatosis (nuclear beta-catenin, CTNNB1 mutation) determines the entire treatment pathway including surgical margins, adjuvant radiation recommendation, systemic therapy eligibility, and surveillance duration. Monitor pathology platforms at 1-minute intervals during business hours.
Long-term sarcoma surveillance platforms must support 20-year follow-up. SFT's late recurrence and distant metastasis biology — where lung metastases may first appear 10–15 years after complete primary resection even for Demicco low-risk tumors — demands surveillance CT chest/abdomen/pelvis at 6-month intervals for the first 5 years then annually for up to 20 years in high-risk cases, requiring platforms that maintain reliable imaging scheduling, result integration, and clinical coordination across an exceptionally long surveillance horizon. Monitor surveillance platforms during business hours with sustained-failure alerting.
What to Monitor on an SFT/HPC Tech Platform
Sarcoma Surgery and Wide Local Excision
Monitor preoperative MRI for tumor characterization and vascular mapping (retroperitoneal SFT, extremity SFT, head and neck SFT), preoperative DSA angiography and embolization coordination records, operative documentation for wide local excision and reconstruction, intraoperative frozen section margin communication records, vascular surgery consultation records for planned IVC or major vessel involvement, and reconstructive surgery documentation (free tissue transfer, mesh reconstruction) at 1-minute intervals during operative sessions. Alert immediately — platform failures during SFT resection eliminate operative documentation access and intraoperative imaging at the moment when margin assessment, vessel reconstruction, and reconstruction approach decisions are being made.
Intracranial SFT/HPC Neurosurgery
Monitor preoperative MRI brain with gadolinium and venous phase CT angiography for venous sinus involvement mapping, intraoperative neuronavigation registration and imaging integration, awake craniotomy functional mapping documentation, operative records for craniotomy and duraplasty, DSA and embolization records for preoperative vascular supply reduction, postoperative neurological assessment, and neurosurgical ICU records at 1-minute intervals during operative and immediate postoperative periods. Alert immediately — neurosurgical platform failures during craniotomy for dural-based SFT/HPC eliminate neuronavigation access and operative documentation at the moment when venous sinus margin decisions and eloquent cortex preservation during debulking determine extent-of-resection outcomes.
Adjuvant Radiation Therapy and Stereotactic Radiosurgery
Monitor IMRT treatment planning records for postoperative tumor bed irradiation (dose-volume histograms, OAR constraints), daily CBCT image guidance verification, treatment delivery records, stereotactic radiosurgery (SRS/FSRT) planning and delivery records for recurrent intracranial SFT, and adaptive replanning documentation at 1-minute intervals during treatment hours. Alert immediately — radiation therapy platform failures during adjuvant IMRT for high-grade SFT or intracranial SFT/HPC interrupt the daily treatment delivery workflow for a patient receiving radiation whose interruption increases recurrence risk.
NAB2-STAT6 Molecular Pathology and Risk Stratification
Monitor STAT6 nuclear immunohistochemistry records and scoring documentation, NAB2-STAT6 fusion variant sequencing records (exon 4-2 versus exon 6-16 fusion correlation with grade), Demicco risk stratification records (patient age, mitotic count, tumor size, necrosis documentation), differential diagnosis exclusion records (SS18-SSX FISH for synovial sarcoma, CTNNB1 for desmoid), CD34 and CD99 IHC documentation, and molecular pathology tumor board records at 1-minute intervals during business hours. Alert immediately — molecular pathology platform failures delay NAB2-STAT6 fusion confirmation and Demicco risk stratification in cases where the molecular result determines adjuvant IMRT recommendation, surveillance protocol intensity, and anti-angiogenic therapy eligibility for recurrent disease.
Preoperative Embolization Planning
Monitor DSA angiography records for hypervascular SFT feeding vessel characterization (embolization candidate identification for large retroperitoneal and intracranial SFT), interventional radiology procedure scheduling and documentation, embolization material records (particles, coils, liquid embolic agents), post-embolization imaging verification, and time-to-surgery coordination records (typically 24–48 hours post-embolization) at 1-minute intervals during procedural hours. Alert immediately — embolization platform failures before planned SFT resection disrupt the preoperative hemorrhage reduction workflow for hypervascular SFT where preoperative embolization substantially reduces intraoperative blood loss and allows a more complete resection.
Anti-Angiogenic Systemic Therapy Management
Monitor sunitinib, pazopanib, and bevacizumab-temozolomide prescribing and pharmacy dispensing records, dose modification documentation for sunitinib (hand-foot syndrome, hypertension, fatigue, thyroid dysfunction), temozolomide toxicity monitoring (myelosuppression, lymphopenia with Pneumocystis prophylaxis indication), tumor response assessment CT/MRI scheduling (RECIST 1.1 measurements for objective response documentation), bevacizumab-related proteinuria and hypertension monitoring records, and clinical trial enrollment documentation for novel SFT therapeutics at 1-minute intervals during clinical hours. Alert immediately — anti-angiogenic therapy platform failures interrupt the prescribing, toxicity monitoring, and dose modification workflow of patients receiving sunitinib, pazopanib, or bevacizumab-temozolomide for recurrent or metastatic SFT where toxicity management determines treatment continuation feasibility.
Long-Term Surveillance and Late Recurrence Detection
Monitor serial CT chest/abdomen/pelvis surveillance scheduling (every 6 months for 5 years, then annually up to 20 years for high-risk SFT), surveillance MRI brain for intracranial SFT/HPC at 6-month intervals (local recurrence detection), comparison imaging measurement and growth rate records, tumor board review documentation for suspicious surveillance findings, biopsy scheduling for recurrent disease, and pulmonary metastasectomy or systemic therapy referral records during business hours. Alert on sustained failures — surveillance delays risk undetected late pulmonary metastases or local recurrence in the 10–20-year follow-up period where SFT's indolent but persistent recurrence risk requires continuous surveillance program reliability.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. SFT programs coordinate across sarcoma surgery, neurosurgery, thoracic surgery, radiation oncology, pathology, medical oncology, and interventional radiology — authentication failures simultaneously block every member of the multidisciplinary team managing a patient whose surgical planning, intraoperative neuronavigation, adjuvant radiation, molecular diagnostics, anti-angiogenic therapy, and decades-long surveillance all require continuous, coordinated platform access.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, surgical planning systems, radiation therapy platforms, molecular pathology systems, pharmacy platforms, and surveillance imaging portals. Certificate errors disrupt the surgical coordination, adjuvant IMRT delivery, pathology reporting, anti-angiogenic therapy management, and long-term surveillance workflows of SFT/HPC management.
HIPAA and Oncology Data Privacy Considerations
SFT/HPC technology platforms handle sensitive PHI including NAB2-STAT6 fusion documentation, Demicco risk stratification records with prognostic implications, intracranial SFT/HPC craniotomy records with neurological deficit documentation, functional brain mapping records for eloquent cortex adjacent tumors, venous sinus involvement operative records, long-term anti-angiogenic therapy prescribing and toxicity records, 10–20-year surveillance imaging archives, and late recurrence and pulmonary metastasis treatment records. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components managing this PHI.
For platforms managing intracranial SFT/HPC records alongside functional neurological mapping documentation — where awake craniotomy records, language and motor mapping findings, and post-resection neurological deficit documentation reflect surgical consequences with profound personal and occupational impact — privacy and availability standards must reflect the sensitivity of combined oncologic and neurological PHI managed across the long natural history of intracranial SFT/HPC. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for sarcoma programs and neuro-oncology programs managing SFT/HPC's intersection of surgical oncology, radiation therapy, molecular diagnostics, and decade-spanning surveillance PHI.
Alerting Strategy for SFT/HPC Tech Platforms
Immediate alerting during operative sessions: Sarcoma surgery planning, intracranial SFT/HPC neuronavigation, preoperative embolization DSA, and operative documentation platforms during active SFT resection or craniotomy. These cannot fail during surgery without direct surgical safety and documentation consequence.
Immediate alerting during treatment sessions: Adjuvant IMRT treatment planning, CBCT image guidance, and stereotactic radiosurgery delivery platforms during active radiation treatment for SFT/HPC.
Immediate business-hours alert: NAB2-STAT6 fusion testing, Demicco risk stratification, anti-angiogenic therapy management, and preoperative embolization coordination platforms. Alert the moment these fail during active clinical encounters.
Sustained-failure alert (10–15 minutes): Long-term sarcoma surveillance imaging scheduling, pulmonary metastasis monitoring, intracranial SFT/HPC MRI surveillance, and tumor registry documentation platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms SFT/HPC platform availability from geographies where specialized sarcoma surgery programs and neuro-oncology centers with SFT/HPC expertise concentrate — important for platforms supporting patients who travel to high-volume centers where SFT's rarity limits operative and radiation oncology experience at regional hospitals.
Status Page for SFT/HPC Care Team Communication
A real-time status page gives sarcoma surgeons planning wide local excision for retroperitoneal SFT, neurosurgeons planning craniotomy for intracranial SFT/HPC, radiation oncologists planning adjuvant IMRT or stereotactic radiosurgery, pathologists issuing NAB2-STAT6 fusion and Demicco risk stratification reports, interventional radiologists performing preoperative embolization, and medical oncologists managing anti-angiogenic therapy for recurrent SFT immediate platform visibility without requiring inbound IT support contact. During a surgical planning platform outage before a craniotomy for a large parasagittal SFT/HPC where the neurosurgeon requires intraoperative neuronavigation access and the operative team cannot access prior MRI brain and venous angiography for superior sagittal sinus involvement mapping, a status page enables immediate contingency protocol activation ensuring that alternative imaging and documentation pathways are coordinated without platform-dependent delay.
Include the status page URL in sarcoma surgery downtime procedures, adjuvant IMRT emergency replanning workflows, pathology laboratory emergency access protocols, and preoperative embolization fallback procedures.
Vigilmon Setup for SFT/HPC Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Sarcoma surgery planning / preoperative MRI / vascular mapping (operative hours) | 1 min | Slack + PagerDuty (surgical hours) | | Intracranial SFT/HPC neurosurgery / neuronavigation / venous sinus mapping | 1 min | Slack + PagerDuty (surgical hours) | | Preoperative embolization / DSA / interventional radiology | 1 min | Slack + PagerDuty (procedural hours) | | Adjuvant IMRT treatment planning and delivery | 1 min | Slack + PagerDuty (treatment hours) | | NAB2-STAT6 fusion testing / Demicco risk stratification | 1 min | Slack + PagerDuty (business hours) | | Anti-angiogenic therapy (sunitinib / pazopanib / bevacizumab-temozolomide) | 1 min | Slack + PagerDuty (business hours) | | Long-term sarcoma surveillance CT / pulmonary metastasis monitoring | 2 min | Slack (business hours) | | Intracranial SFT/HPC MRI surveillance (local recurrence) | 2 min | Slack (business hours) | | Tumor board review / recurrence biopsy scheduling | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure sarcoma surgery planning and preoperative MRI with immediate alerting during operative sessions
- Add intracranial SFT/HPC neuronavigation and venous sinus mapping with immediate alerting during craniotomy
- Configure preoperative embolization DSA platforms with immediate alerting during procedural hours
- Add adjuvant IMRT planning and delivery platforms with immediate alerting during treatment hours
- Configure NAB2-STAT6 fusion testing and Demicco risk stratification with immediate business-hours alerting
- Add anti-angiogenic therapy management with immediate clinical-hours alerting
- Configure long-term sarcoma surveillance CT and pulmonary metastasis monitoring with sustained-failure alerting
- Add intracranial SFT/HPC MRI surveillance for local recurrence with sustained-failure alerting
- Configure tumor board review and recurrence biopsy scheduling with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, surgical planning, radiation therapy, pathology, and surveillance domains
- Add the status page URL to sarcoma surgery downtime procedures, adjuvant IMRT emergency replanning workflows, and embolization consultation fallback protocols
Conclusion
SFT/HPC technology platforms are embedded in clinical decisions where preoperative embolization and neurosurgical planning platform availability before a craniotomy for a large right occipital parasagittal SFT/HPC with superior sagittal sinus involvement in a 52-year-old patient — where the neurosurgeon reviewing MRI brain with venous phase CT angiography for sinus patency assessment and collateral venous drainage mapping to determine whether sinus sacrifice is feasible or requires reconstruction, the interventional neuroradiologist performing preoperative embolization via angiogram to reduce the characteristically hypervascular SFT/HPC's intraoperative blood loss, the radiation oncologist reviewing preoperative imaging for adjuvant IMRT target volume delineation before a planned subtotal resection approach preserving functional parietal cortex, and the pathologist confirming prior biopsy STAT6 nuclear immunoreactivity and NAB2-STAT6 fusion for WHO grade 3 SFT/HPC classification that determines postoperative radiation recommendation — cannot be interrupted by platform outage at the precise moment when neurosurgical approach selection, embolization procedure execution, radiation target planning, and molecular classification must be simultaneously integrated into the operative and postoperative treatment plan; where adjuvant IMRT treatment planning platform availability during the post-craniotomy radiation planning period — where the radiation oncologist designing fractionated stereotactic radiotherapy delivering 60 Gy in 30 fractions to the intracranial SFT/HPC tumor bed and residual enhancing disease requires treatment planning system access for dose-volume histogram optimization, brainstem and optic apparatus constraint verification for a posterior fossa adjacent target, simulation CT-to-MRI fusion for accurate GTV delineation, and plan approval before simulation-to-first-fraction interval exceeds the clinical timeline — cannot be delayed by platform unavailability when the WHO grade 3 SFT/HPC's local recurrence rate without adjuvant radiation approaches 50–90% and the post-resection window for timely radiation initiation determines long-term local control outcomes; and where long-term sarcoma surveillance platform availability during the 12-year follow-up CT chest for a 61-year-old woman whose retroperitoneal SFT was completely resected 12 years earlier with Demicco intermediate risk classification — where comparison of the current CT with the 11-year surveillance imaging confirms a new 1.5 cm pulmonary nodule in the right lower lobe not present on prior imaging that warrants CT-guided biopsy to determine whether this represents a first late pulmonary metastasis amenable to metastasectomy or pulmonary anti-angiogenic therapy initiation — determines whether the characteristically late metastatic behavior of SFT is detected at the earliest timepoint where therapeutic intervention can offer the longest possible disease control. A neuronavigation platform that fails when the neurosurgeon is resecting a dural-based SFT/HPC with venous sinus proximity where real-time navigation guidance determines the boundary between safe maximal resection and sinus sacrifice, an adjuvant IMRT treatment planning platform inaccessible when the radiation oncologist must complete and approve the plan before the next simulation-to-treatment interval expires for a patient with WHO grade 3 SFT/HPC where radiation delay increases local recurrence risk, a surveillance CT platform unavailable when a sarcoma tumor board must compare a new pulmonary nodule against 12-year surveillance imaging archives to determine whether urgent biopsy and metastasectomy planning is warranted — these are not IT incidents. They are clinical disruptions in the management of a rare mesenchymal neoplasm whose long natural history, late recurrence biology, and surgical complexity at multiple anatomical sites require that surgical planning, radiation delivery, molecular diagnostics, anti-angiogenic therapy, and decade-spanning surveillance platforms are reliably available across the 20-year clinical horizon that SFT/HPC management demands.
Uptime monitoring gives SFT/HPC tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to sarcoma surgery programs, neuro-oncology programs, radiation oncology departments, molecular pathology laboratories, and compliance auditors that platform operational reliability matches the surgical complexity, radiation precision, molecular diagnostic demands, and 20-year surveillance obligations of modern SFT/HPC care.
Start monitoring your hemangiopericytoma / solitary fibrous tumor care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #hemangiopericytoma #solitaryfibroustumor #SFT #HPC #NAB2STAT6 #STAT6 #sarcoma #neurooncology #craniotomy #IMRT #neuronavigation #embolization #antiangiogenic #sunitinib #pazopanib #softtissuesarcoma #raretumormonitoring #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre